Form 4 holding
Director
KALA BIO, Inc.
- Security class
- Common Stock
- Shares / value
- 35,932
- Estimated value
- $73,660
- Report date
- 22 Oct 2025
- Price
- $2.05
- Ownership
- Direct
Todd Bazemore
Insider Reports History
- Reporting-owner location
- Burlington, MA
- Latest reporting-owner signature
-
/s/ Mary Reumuth, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Todd Bazemore
Form 4 holding
Director
KALA BIO, Inc.
- Security class
- Common Stock
- Shares / value
- 1
- Estimated value
- $2
- Report date
- 22 Oct 2025
- Price
- $2.05
- Ownership
- By son
Form 4 holding
Director
KALA BIO, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 180,000
- Estimated value
- Report date
- 29 Aug 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Pulmatrix, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 1,700
- Estimated value
- Report date
- 26 Jan 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Todd Bazemore
4
KALA
KALA BIO, Inc.
- Report period
- 22 Oct 2025
- Transactions
- 1
- Transaction value
- -$39,647
- Accepted by SEC
- 24 Oct 2025, 20:00
- Role
- Director
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 29 Aug 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Sep 2025, 16:08
- Role
- President and Chief Executive Officer, Director
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 24 Jun 2025
- Transactions
- 1
- Transaction value
- -$16,273
- Accepted by SEC
- 26 Jun 2025, 20:00
- Role
- Interim Chief Executive Officer, President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 03 Jun 2025
- Transactions
- 1
- Transaction value
- -$12,679
- Accepted by SEC
- 04 Jun 2025, 20:00
- Role
- Interim Chief Executive Officer, President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 07 Mar 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Mar 2025, 20:00
- Role
- Interim Chief Executive Officer, President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 06 Jan 2025
- Transactions
- 3
- Transaction value
- -$15,207
- Accepted by SEC
- 07 Jan 2025, 20:14
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 26 Jun 2024
- Transactions
- 1
- Transaction value
- -$22,102
- Accepted by SEC
- 27 Jun 2024, 20:00
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 31 May 2024
- Transactions
- 1
- Transaction value
- -$12,746
- Accepted by SEC
- 03 Jun 2024, 20:00
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
KALA BIO, Inc.
- Report period
- 04 Jan 2024
- Transactions
- 3
- Transaction value
- -$9,470
- Accepted by SEC
- 05 Jan 2024, 16:03
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
Kala Pharmaceuticals, Inc.
- Report period
- 22 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 23 Jun 2023, 20:00
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
Kala Pharmaceuticals, Inc.
- Report period
- 31 May 2023
- Transactions
- 9
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2023, 20:00
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
Kala Pharmaceuticals, Inc.
- Report period
- 14 Mar 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Mar 2023, 20:00
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
PULM
Pulmatrix, Inc.
- Report period
- 26 Jan 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 30 Jan 2023, 15:05
- Role
- Director
- Next action
- Open filing details
4
KALA
Kala Pharmaceuticals, Inc.
- Report period
- 04 Jan 2023
- Transactions
- 2
- Transaction value
- -$1,769
- Accepted by SEC
- 06 Jan 2023, 19:00
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
Kala Pharmaceuticals, Inc.
- Report period
- 26 Oct 2022
- Transactions
- 1
- Transaction value
- -$1,393
- Accepted by SEC
- 28 Oct 2022, 16:15
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
Kala Pharmaceuticals, Inc.
- Report period
- 27 Jun 2022
- Transactions
- 1
- Transaction value
- -$1,144
- Accepted by SEC
- 29 Jun 2022, 20:10
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
PULM
Pulmatrix, Inc.
- Report period
- 27 Jan 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 28 Jan 2022, 19:44
- Role
- Director
- Next action
- Open filing details
4
KALA
Kala Pharmaceuticals, Inc.
- Report period
- 03 Jan 2022
- Transactions
- 2
- Transaction value
- -$4,490
- Accepted by SEC
- 05 Jan 2022, 19:00
- Role
- President and Chief Operating Officer
- Next action
- Open filing details
4
KALA
Kala Pharmaceuticals, Inc.
- Report period
- 26 Oct 2021
- Transactions
- 1
- Transaction value
- -$22,579
- Accepted by SEC
- 28 Oct 2021, 20:03
- Role
- CHIEF OPERATING OFFICER
- Next action
- Open filing details
4
KALA
Kala Pharmaceuticals, Inc.
- Report period
- 28 Jun 2021
- Transactions
- 1
- Transaction value
- -$16,796
- Accepted by SEC
- 29 Jun 2021, 17:25
- Role
- CHIEF OPERATING OFFICER
- Next action
- Open filing details